相关实验视频
Updated: Jan 17, 2026

06:03
Delivery of Modified mRNA in a Myocardial Infarction Mouse Model
Published on: June 11, 2020
9.6K
作为内源性心脏再生代谢重编程调节器的长非编码RNA:机制和治疗潜力
Xueping Wu1, Yehui Lv2, Zhihong Li2
1Department of Anatomy, Histology and Embryology; Institute of Wound Prevention and Treatment, Shanghai University of medicine & Health Sciences, 279 Zhouzhu Road, Pudong New District, Shanghai, China.
Biomedical journal
|September 17, 2025
概括
心肌梗塞 (MI) 恢复在成年人中是有限的,因为心肌细胞再生不良. 本综述探讨了非编码RNAs (lncRNAs) 和代谢转变影响心脏中风后心脏修复的时间,寻找新的治疗点.
科学领域:
- 心血管生物学 心血管生物学
- 分子医学是分子医学.
- 再生医学是一种再生医学.
背景情况:
- 心肌梗塞 (MI) 仍然是全球主要的死亡原因,尽管治疗进展,死亡率仍然很高.
- 成年哺乳动物的心脏在心脏病发作后具有有限的再生能力,导致功能受损和心力衰竭.
- 新生儿心脏表现出再生潜力,出生后的再生潜力下降,与代谢变化相吻合.
研究的目的:
- 审查长非编码RNAs (lncRNAs) 在协调心脏再生中的作用.
- 为了研究 lncRNAs 和代谢重编程在MI后心肌再生中的相互作用.
- 确定新的治疗点,以加强心肌梗塞后的心脏修复.
主要方法:
- 文献综述侧重于lncRNAs,代谢重编程和心脏再生.
- 对表观遗传控制,代谢途径和miRNA由lncRNAs进行海绵化的分析.
- 综合目前对心肌修复中的分子机制的理解.
主要成果:
- lncRNAs通过表观遗传修饰,代谢重编程和miRNA海绵化来调节心脏再生.
- 代谢变化,包括减少糖解和增加脂肪酸氧化,影响心肌细胞的增殖.
- 像Bvht,GATA6-AS1和CAREL这样的特定的lncRNA参与控制这些过程.
结论:
- 了解lncRNA-代谢轴对于推进心肌梗塞治疗方法至关重要.
- 针对lncRNAs和代谢途径提供了增强心肌再生的潜在策略.
- 需要进一步的研究,以充分阐明这些机制的临床应用.
更多相关视频
相关概念视频
lncRNA - Long Non-coding RNAs
9.8K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.8K
lncRNA - Long Non-coding RNAs
3.5K
3.5K
Formation of Muscle Fibers from Myoblasts
5.8K
De novo myogenesis, or the formation of muscle fibers, begins during the early embryonic stages. The skeletal muscle is formed from somites– blocks of embryonic cell layers. The somites are further divided into dermatomes, myotomes, sclerotomes, and syndetomes. Among these, the myotomes give rise to muscle fibers.
Muscle progenitor cells (MPCs) are formed from the myotomes. MPCs express genes that encode the transcription factors Pax3 and Pax7. Along with Pax 3/7, other transcription...
Muscle progenitor cells (MPCs) are formed from the myotomes. MPCs express genes that encode the transcription factors Pax3 and Pax7. Along with Pax 3/7, other transcription...
5.8K
Regulation of Heart Rates
3.8K
The regulation of heart rate is a complex process controlled by the autonomic nervous system (ANS), hormonal influences, and intrinsic cardiac mechanisms. The ANS has two main components: the sympathetic nervous system (SNS) and the parasympathetic nervous system (PNS).
The SNS increases heart rate through the release of norepinephrine and epinephrine, which act on beta-1 adrenergic receptors in the heart. This action increases the rate of depolarization in the sinoatrial (SA) node, the heart's...
The SNS increases heart rate through the release of norepinephrine and epinephrine, which act on beta-1 adrenergic receptors in the heart. This action increases the rate of depolarization in the sinoatrial (SA) node, the heart's...
3.8K
Types of RNA
9.1K
Three main types of RNA are involved in protein synthesis: messenger RNA (mRNA), transfer RNA (tRNA), and ribosomal RNA (rRNA). These RNAs perform diverse functions and can be broadly classified as protein-coding or non-coding RNA. Non-coding RNAs play important roles in regulating gene expression in response to developmental and environmental changes. Non-coding RNAs in prokaryotes can be manipulated to develop more effective antibacterial drugs for human or animal use.
RNA Performs Diverse...
RNA Performs Diverse...
9.1K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
942
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
942

